CUSIP: 58490H107
Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
4,083,323
-
Share change
-
+1,418,842
-
Total reported value
-
$6,665,000
-
Price per share
-
$1.63
-
Number of holders
-
22
-
Value change
-
+$2,214,910
-
Number of buys
-
9
-
Number of sells
-
9
Quarterly Holders Quick Answers
What is CUSIP 58490H107?
CUSIP 58490H107 identifies MDNAF - Medicenna Therapeutics Corp. - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q1 2022
-
Previous quarter:
Q3 2021
Recent filing periods for CUSIP 58490H107:
Institutional Holders of Medicenna Therapeutics Corp. - COM (MDNAF) as of Q4 2021
As of 31 Dec 2021,
Medicenna Therapeutics Corp. - COM (MDNAF) was held by
22 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,083,323 shares.
The largest 10 holders included
AIGH Capital Management LLC, Verition Fund Management LLC, Worth Venture Partners, LLC, ACT CAPITAL MANAGEMENT, LLC, Sigma Planning Corp, LETKO, BROSSEAU & ASSOCIATES INC, RENAISSANCE TECHNOLOGIES LLC, TOCQUEVILLE ASSET MANAGEMENT L.P., Vident Investment Advisory, LLC, and Rathbones Group PLC.
This page lists
22
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.